{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T14:58:38Z","timestamp":1767020318148,"version":"3.48.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Taiwan Ministry of Health and Welfare Clinical Trial Center","award":["MOHW113-TDU-B-212-114009"],"award-info":[{"award-number":["MOHW113-TDU-B-212-114009"]}]},{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"crossref","award":["DMR-111-105; DMR-112-087; DMR-113-009; DMR-113-156; DMR-114-046; DMR-114-139"],"award-info":[{"award-number":["DMR-111-105; DMR-112-087; DMR-113-009; DMR-113-156; DMR-114-046; DMR-114-139"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abatract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\u00a0<\/jats:title>\n                    <jats:p>Sensorineural hearing loss (SNHL) is a common but underrecognized complication of type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) use was associated with favorable renal and cardiovascular outcomes beyond glycemic control, but their impact on auditory outcomes remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a nationwide cohort study using Taiwan\u2019s National Health Insurance Research Database (2000\u20132021). Patients with T2DM who received SGLT2i for \u2265\u200990 days were compared with matched non-users. Propensity score matching was applied 1:1 based on demographic, clinical, and treatment characteristics. The primary outcome was the incidence of SNHL, confirmed by audiometric testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 381,592 patients with type 2 diabetes mellitus (T2DM) were included. Compared with non-users, SGLT2i users exhibited a significantly lower risk of SNHL (adjusted hazard ratios (aHRs)\u2009=\u20090.84; 95% CI: 0.75\u20130.94). Subgroup analyses confirmed a consistent lower risk across sex, age, urbanization, and comorbidity strata. Notably, long-term SGLT2i use (\u2265\u2009366 days) showed a strong dose\u2013response association with reduced SNHL risk (aHR\u2009=\u20090.32; 95% CI: 0.27\u20130.39).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2i use in T2DM patients is associated with a reduced risk of SNHL, particularly with sustained therapy. These findings highlight a potential association between SGLT2i use and a lower risk of auditory complications in diabetes, underscoring the importance of considering hearing health within comprehensive diabetes management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13098-025-02026-7","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T14:55:03Z","timestamp":1767020103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The relationship between SGLT2 inhibitors and hearing loss: a nationwide population-based retrospective cohort study"],"prefix":"10.1186","volume":"17","author":[{"given":"Chia-Huei","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chao","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Yin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu-Lung","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng-Jun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Der-Yang","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuang-Hsi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"1","key":"2026_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s10020-023-00737-z","volume":"29","author":"Y Deng","year":"2023","unstructured":"Deng Y, Chen S, Hu J. Diabetes mellitus and hearing loss. Mol Med. 2023;29(1):141.","journal-title":"Mol Med"},{"issue":"1","key":"2026_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1210\/jc.2012-2119","volume":"98","author":"C Horikawa","year":"2013","unstructured":"Horikawa C, Kodama S, Tanaka S, Fujihara K, Hirasawa R, Yachi Y, et al. Diabetes and risk of hearing impairment in adults: a meta-analysis. J Clin Endocrinol Metab. 2013;98(1):51\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-149-1-200807010-00231","volume":"149","author":"KE Bainbridge","year":"2008","unstructured":"Bainbridge KE, Hoffman HJ, Cowie CC. Diabetes and hearing impairment in the United States: audiometric evidence from the National health and nutrition examination Survey, 1999 to 2004. Ann Intern Med. 2008;149(1):1\u201310.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2026_CR4","doi-asserted-by":"publisher","first-page":"e081035","DOI":"10.1136\/bmjopen-2023-081035","volume":"14","author":"S Asghar","year":"2024","unstructured":"Asghar S, Ali Z, Abdullah A, Naveed S, Ahmad MS, Rafi TSM. Sensorineural hearing loss among type 2 diabetic patients and its association with peripheral neuropathy: a cross-sectional study from a lower middle-income country. BMJ Open. 2024;14(5):e081035.","journal-title":"BMJ Open"},{"key":"2026_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","volume":"66","author":"V Vallon","year":"2015","unstructured":"Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255\u201370.","journal-title":"Annu Rev Med"},{"issue":"1","key":"2026_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","volume":"32","author":"EC Chao","year":"2014","unstructured":"Chao EC. SGLT-2 inhibitors: a new mechanism for glycemic control. Clin Diabetes. 2014;32(1):4\u201311.","journal-title":"Clin Diabetes"},{"issue":"10166","key":"2026_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"issue":"24","key":"2026_CR8","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"4","key":"2026_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"key":"2026_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-1-4615-1203-5_8","volume-title":"Molecular biology and physiology of water and solute transport","author":"E Beitz","year":"2000","unstructured":"Beitz E, Kumagami H, Ruppersberg JP, Schultz JE, Agre P. The kidney in the inner ear. In: Hohmann S, Nielsen S, editors. Molecular biology and physiology of water and solute transport. Boston, MA: Springer US; 2000. pp. 59\u201362."},{"key":"2026_CR11","doi-asserted-by":"crossref","unstructured":"Walker EM Jr., Fazekas-May MA, Bowen WR. Nephrotoxic and ototoxic agents. Clin Lab Med. 1990;10(2):323\u201354.","DOI":"10.1016\/S0272-2712(18)30572-9"},{"issue":"4","key":"2026_CR12","doi-asserted-by":"publisher","first-page":"C1187","DOI":"10.1152\/ajpcell.00024.2007","volume":"293","author":"F Lang","year":"2007","unstructured":"Lang F, Vallon V, Knipper M, Wangemann P. Functional significance of channels and transporters expressed in the inner ear and kidney. Am J Physiol Cell Physiol. 2007;293(4):C1187\u2013208.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"2026_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dci19-0074","volume":"43","author":"M Packer","year":"2020","unstructured":"Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020;43(3):508\u201311.","journal-title":"Diabetes Care"},{"key":"2026_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10081166","author":"KF Tsai","year":"2021","unstructured":"Tsai KF, Chen YL, Chiou TT, Chu TH, Li LC, Ng HY, et al. Emergence of SGLT2 inhibitors as powerful antioxidants in human diseases. Antioxidants. 2021. https:\/\/doi.org\/10.3390\/antiox10081166.","journal-title":"Antioxidants"},{"issue":"4","key":"2026_CR15","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1002\/jcp.26760","volume":"234","author":"H Yaribeygi","year":"2019","unstructured":"Yaribeygi H, Atkin SL, Butler AE, Sahebkar A. Sodium-glucose cotransporter inhibitors and oxidative stress: an update. J Cell Physiol. 2019;234(4):3231\u20137.","journal-title":"J Cell Physiol"},{"issue":"4","key":"2026_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334.","journal-title":"N Engl J Med"},{"issue":"5","key":"2026_CR17","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","volume":"21","author":"T Toyama","year":"2019","unstructured":"Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237\u201350.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"2026_CR18","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.puhe.2006.06.011","volume":"120","author":"N Huang","year":"2006","unstructured":"Huang N, Yip W, Chang HJ, Chou YJ. Trends in rural and urban differentials in incidence rates for ruptured appendicitis under the National health insurance in Taiwan. Public Health. 2006;120(11):1055\u201363.","journal-title":"Public Health"},{"issue":"15","key":"2026_CR19","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"key":"2026_CR20","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2018062","volume":"40","author":"LY Lin","year":"2018","unstructured":"Lin LY, Warren-Gash C, Smeeth L, Chen PC. Data resource profile: the National Health Insurance Research Database (NHIRD). Epidemiol Health. 2018;40:e2018062.","journal-title":"Epidemiol Health"},{"issue":"3","key":"2026_CR21","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/lary.22480","volume":"122","author":"RJ Lin","year":"2012","unstructured":"Lin RJ, Krall R, Westerberg BD, Chadha NK, Chau JK. Systematic review and meta-analysis of the risk factors for sudden sensorineural hearing loss in adults. Laryngoscope. 2012;122(3):624\u201335.","journal-title":"Laryngoscope"},{"key":"2026_CR22","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1007\/s00405-013-2379-2","volume":"270","author":"P Salvago","year":"2013","unstructured":"Salvago P, Martines E, Martines F. Prevalence and risk factors for sensorineural hearing loss: Western Sicily overview. Eur Arch Otorhinolaryngol. 2013;270:3049\u201356.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"2026_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/lary.30141","volume":"133","author":"JFCPM Sim\u00f5es","year":"2023","unstructured":"Sim\u00f5es JFCPM, Vlaminck S, Sei\u00e7a RMF, Acke F, Migu\u00e9is ACE. Cardiovascular risk and sudden sensorineural hearing loss: a systematic review and meta-analysis. Laryngoscope. 2023;133(1):15\u201324.","journal-title":"Laryngoscope"},{"issue":"6","key":"2026_CR24","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228\u201334.","journal-title":"Commun Stat Simul Comput"},{"key":"2026_CR25","doi-asserted-by":"publisher","first-page":"774585","DOI":"10.3389\/fnins.2021.774585","volume":"15","author":"W Yu","year":"2021","unstructured":"Yu W, Zong S, Du P, Zhou P, Li H, Wang E, et al. Role of the stria vascularis in the pathogenesis of sensorineural hearing loss: a narrative review. Front Neurosci. 2021;15:774585.","journal-title":"Front Neurosci"},{"issue":"6146","key":"2026_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/330379a0","volume":"330","author":"MA Hediger","year":"1987","unstructured":"Hediger MA, Coady MJ, Ikeda TS, Wright EM. Expression cloning and cDNA sequencing of the Na+\/glucose co-transporter. Nature. 1987;330(6146):379\u201381.","journal-title":"Nature"},{"key":"2026_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.749010","volume":"12","author":"J Shaffner","year":"2021","unstructured":"Shaffner J, Chen B, Malhotra DK, Dworkin LD, Gong R. Therapeutic targeting of SGLT2: a new era in the treatment of diabetes and diabetic kidney disease. Front Endocrinol (Lausanne). 2021;12:749010.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1\u20132","key":"2026_CR28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/0378-5955(93)90039-4","volume":"71","author":"M Ito","year":"1993","unstructured":"Ito M, Spicer SS, Schulte BA. Immunohistochemical localization of brain type glucose transporter in mammalian inner ears: comparison of developmental and adult stages. Hear Res. 1993;71(1\u20132):230\u20138.","journal-title":"Hear Res"},{"issue":"1\u20132","key":"2026_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0378-5955(90)90166-M","volume":"47","author":"S Wang","year":"1990","unstructured":"Wang S, Schacht J. Insulin stimulates protein synthesis and phospholipid signaling systems but does not regulate glucose uptake in the inner ear. Hear Res. 1990;47(1\u20132):53\u201361.","journal-title":"Hear Res"},{"issue":"1\u20132","key":"2026_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0378-5955(97)00157-3","volume":"114","author":"S Takeuchi","year":"1997","unstructured":"Takeuchi S, Ando M. Marginal cells of the stria vascularis of gerbils take up glucose via the facilitated transporter GLUT: application of autofluorescence. Hear Res. 1997;114(1\u20132):69\u201374.","journal-title":"Hear Res"},{"issue":"1","key":"2026_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0165-0173(03)00189-9","volume":"43","author":"T Nakashima","year":"2003","unstructured":"Nakashima T, Naganawa S, Sone M, Tominaga M, Hayashi H, Yamamoto H, et al. Disorders of cochlear blood flow. Brain Res Brain Res Rev. 2003;43(1):17\u201328.","journal-title":"Brain Res Brain Res Rev"},{"issue":"4","key":"2026_CR32","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1177\/0394632016673845","volume":"29","author":"A Ciorba","year":"2016","unstructured":"Ciorba A, Corazzi V, Bianchini C, Aimoni C, Skarzynski H, Skarzynski PH, et al. Sudden sensorineural hearing loss: is there a connection with inner ear electrolytic disorders? A literature review. Int J Immunopathol Pharmacol. 2016;29(4):595\u2013602.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1","key":"2026_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12955-018-0921-z","volume":"16","author":"YM Lee","year":"2018","unstructured":"Lee YM, Kim RB, Lee HJ, Kim K, Shin MH, Park HK, et al. Relationships among medication adherence, lifestyle modification, and health-related quality of life in patients with acute myocardial infarction: a cross-sectional study. Health Qual Life Outcomes. 2018;16(1):100.","journal-title":"Health Qual Life Outcomes"},{"issue":"15","key":"2026_CR34","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.2169\/internalmedicine.0701-17","volume":"57","author":"S Sugiyama","year":"2018","unstructured":"Sugiyama S, Jinnouchi H, Kurinami N, Hieshima K, Yoshida A, Jinnouchi K, et al. The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus. Intern Med. 2018;57(15):2147\u201356.","journal-title":"Intern Med"},{"key":"2026_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084146","author":"M Teraoka","year":"2024","unstructured":"Teraoka M, Hato N, Inufusa H, You F. Role of oxidative stress in sensorineural hearing loss. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25084146.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2026_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0135-z","volume":"9","author":"CMO Volpe","year":"2018","unstructured":"Volpe CMO, Villar-Delfino PH, Dos Anjos PMF, Nogueira-Machado JA. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis. 2018;9(2):119.","journal-title":"Cell Death Dis"},{"key":"2026_CR37","doi-asserted-by":"publisher","unstructured":"Pawlos A, Broncel M, Wozniak E, Gorzelak-Pabis P. Neuroprotective Effect of SGLT2 Inhibitors. Molecules. 2021;26(23): 7213. https:\/\/doi.org\/10.3390\/molecules26237213","DOI":"10.3390\/molecules26237213"},{"key":"2026_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13040652","author":"A Pisani","year":"2023","unstructured":"Pisani A, Paciello F, Del Vecchio V, Malesci R, De Corso E, Cantone E, et al. The role of BDNF as a biomarker in cognitive and sensory neurodegeneration. J Pers Med. 2023; 13(4):652. https:\/\/doi.org\/10.3390\/jpm13040652.","journal-title":"J Pers Med"},{"key":"2026_CR39","doi-asserted-by":"crossref","unstructured":"Wicinski M, Wodkiewicz E, Gorski K, Walczak M, Malinowski B. Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer\u2019s Disease and Ischemia-Related Brain Injury. Pharmaceuticals (Basel). 2020;13(11).","DOI":"10.3390\/ph13110379"},{"key":"2026_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001238","author":"AP McGovern","year":"2020","unstructured":"McGovern AP, Hogg M, Shields BM, Sattar NA, Holman RR, Pearson ER, et al. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ open diabetes research & care. 2020. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001238.","journal-title":"BMJ open diabetes research & care"},{"issue":"6","key":"2026_CR41","doi-asserted-by":"publisher","first-page":"837","DOI":"10.4103\/ijem.IJEM_159_17","volume":"22","author":"A Unnikrishnan","year":"2018","unstructured":"Unnikrishnan A, Kalra S, Purandare V, Vasnawala H. Genital infections with sodium glucose cotransporter-2 inhibitors: occurrence and management in patients with type 2 diabetes mellitus. Indian J Endocrinol Metab. 2018;22(6):837\u201342.","journal-title":"Indian J Endocrinol Metab"},{"issue":"3","key":"2026_CR42","doi-asserted-by":"publisher","first-page":"927","DOI":"10.4103\/jfmpc.jfmpc_644_21","volume":"11","author":"S Dutta","year":"2022","unstructured":"Dutta S, Kumar T, Singh S, Ambwani S, Charan J, Varthya SB. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis. J Family Med Prim Care. 2022;11(3):927\u201340.","journal-title":"J Family Med Prim Care"},{"issue":"4","key":"2026_CR43","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jamasurg.2024.7082","volume":"160","author":"AA Dixit","year":"2025","unstructured":"Dixit AA, Bateman BT, Hawn MT, Odden MC, Sun EC. Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis. JAMA Surg. 2025;160(4):423\u201330.","journal-title":"JAMA Surg"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-02026-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T14:55:05Z","timestamp":1767020105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-025-02026-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2026"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-02026-7","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The NHIRD ensures the protection of patient information by using data encryption to maintain confidentiality. For research purposes, it assigns de-identified codes that link to claims records, which include demographic details, healthcare utilization, and prescribed medications. Consequently, individual patient consent is not necessary for accessing NHIRD data in this study. This project was reviewed by the Institutional Review Board (IRB) of China Medical University and granted an exemption (Approval No. CMUH110-REC3-133(CR-3)), with the requirement for informed consent formally waived. All study procedures adhered to applicable ethical standards and regulatory guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to publish the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"459"}}